Dante Genomics , a global leader in genomics and precision medicine, announced a strategic AI collaboration with Amazon Web Services (AWS) to bring generative AI to the clinical care of patients with genetic diseases.
Dante Genomics’ early focus on whole-genome sequencing gives the company a natural competitive advantage in creating large language models (LLMs) for clinical genomics. Each genome contains 10,000 times more data than a traditional genetic panel and more than 20 times more data than whole exome sequencing.
“While companies debated whether the exome contained too much data, we focused on whole-genome sequencing,” said Mattia Capulli , PhD, co-founder and chief scientific officer of Dante Genomics. “It wasn’t easy, but the time and effort involved The strategic investments have paid off and given us an amazing data source to advance clinical genomics LLMs.”
Dante Genomics leverages the Amazon Bedrock Large Language Model (LLM) on the AWS platform to provide Dante customers with greater access and navigation of the extensive and growing collection of more than 130 genomic reports with genomic applications in various clinical areas , including proactive screening, longevity and personalized medicine.
Also Read: Fractyl Health Welcomes Dr. Timothy Kieffer as Chief Scientific Officer
“For more than seven years, Dante Genomics has consistently pursued its mission to provide large-scale whole-genome sequencing. With an ever-growing database, we are unmatched in our expertise in the clinical utility of the genome,” said Andrea Riposati, co-founder and CEO of Dante Genomics. “By partnering with the technology experts at AWS, the Amazon Bedrock platform will help us make the everyday “To revolutionize the application of genomic data in personalized medicine and achieve better health outcomes based on genomic data.”
As part of this collaboration, Dante Genomics aims to make it possible to explore a subset of phenotypes such as eye color, ancestry and monogenetic disorders such as cardiomyopathies, respiratory diseases and seizures via a chat-like interface.
This is a groundbreaking use case for LLMs in genomic medicine, based on extensive research into training honest and responsible AI systems. The system will communicate the result of the genetic derivation to the patient, allow the patient to easily identify comorbidities and request additional information, as well as accurately identify when to seek medical attention.
SOURCE: PRNewswire
